The difference between adagrasib and sotoracib (AMG510)
Currently targetingKRAS There are only two drugs targeting G12Cmutations in the worldadagrasib and sotorasibu (AMG510). Sotoraxib is the first KRAS approved after nearly 40 years of research.KRAStargeted drug, which was approved for marketing in20215Menstrual AmericaFDA, and adagrasib is the second KRAS approved for marketing G12Cinhibitors.

The R&D manufacturers of adagratib and sotolatib are different.
Sotorasibu was developed by Japan's Amgen (Amgen), and adagrasibu was developed by Mirati Therapeutics. The launch times are different, sotorasiib will be released in20215Menstrual America FDA has been approved for marketing, and adagrasib has been launched in the United States in December 2022.
There are different dosages of adagrasib and sotorasib
The recommended dose of adagrasiib is 600 mg orally twice daily until disease progression or unacceptable toxicity. The recommended dose of sotoraxib is 960 mg per day, taken orally once a day, until disease progression or unacceptable toxicity occurs.
Clinical data differ between adagrasiib and sotorasiib
Half-life of adagrasib23 hours, disease control rate (DCR)96%, objective response rate (ORR) 45%, duration of response (DOR) 6.5 months, median progression-free survival (mPFS) 11.1 months, median overall survival (mOS< span>)12.6 months, the incidence of adverse reactions is 85%, and the incidence of adverse reactions grade 3 or above is 30%. The half-life of sotoraxib5.5 hours, disease control rate (DCR) 80.6%, objective response rate (
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)